Stock 1541 IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Biotechnology & Medical Research

Delayed Hong Kong S.E.
Other stock markets
 11:02:50 2024-05-08 pm EDT 		5-day change 1st Jan Change
15.42 HKD +2.94% Intraday chart for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. +4.48% -48.49%
Apr. 17 ImmuneOnco Obtains Chinese Nod for Phase III Trials of Anti-Cancer Medication MT
Apr. 17 ImmuneOnco Biopharmaceuticals Inc. Receives Approval from the National Medical Products Administration of the People's Republic of China for the Protocol of the Phase Iii Clinical Trial of IMM01 CI

Valuation

Fiscal Period: December 2023 2024 2025
Capitalization 1 5,181 5,181 -
Enterprise Value (EV) 1 9,872 4,687 4,635
P/E ratio - - -
Yield - - -
Capitalization / Revenue 26,343 x 8,804 x 6,953 x
EV / Revenue 25,574 x 7,965 x 6,220 x
EV / EBITDA -27.5 x -12.4 x -9.64 x
EV / FCF - - -
FCF Yield - - -
Price to Book 13.6 x 13.4 x -51.3 x
Nbr of stocks (in thousands) 374,158 374,158 -
Reference price 2 13.85 13.85 13.85
Announcement Date 3/25/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2023 2024 2025
Net sales 1 0.386 0.5885 0.7451
EBITDA 1 -359.6 -379.4 -480.8
EBIT 1 -372 -390.4 -490.4
Operating Margin -96,368.39% -66,337.79% -65,820.02%
Earnings before Tax (EBT) - - -
Net income - - -
Net margin - - -
EPS - - -
Free Cash Flow - - -
FCF margin - - -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share 2 - - -
Announcement Date 3/25/24 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2023 2024 2025
Net Debt 1 - - -
Net Cash position 1 297 494 547
Leverage (Debt/EBITDA) - - -
Free Cash Flow - - -
ROE (net income / shareholders' equity) -49.7% -67.2% -845%
ROA (Net income/ Total Assets) - - -
Assets - - -
Book Value Per Share 2 2.000 1.030 -0.2700
Cash Flow per Share - - -
Capex - - -
Capex / Sales - - -
Announcement Date 3/25/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
13.85 CNY
Average target price
15.13 CNY
Spread / Average Target
+9.27%
Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC. Stock ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
-48.49% 690M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.93% 106B
ARGENX SE Stock argenx SE
+7.02% 23.47B
BIONTECH SE Stock BioNTech SE
-14.60% 21.9B
GENMAB A/S Stock Genmab A/S
-7.05% 18.77B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.55% 17.85B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.83% 16.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.51% 14.41B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.49% 12.86B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+329.39% 8.78B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 1541 Stock
  4. Financials ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW